AU2014269028A1 - Angiotensins in muscular dystrophy - Google Patents

Angiotensins in muscular dystrophy Download PDF

Info

Publication number
AU2014269028A1
AU2014269028A1 AU2014269028A AU2014269028A AU2014269028A1 AU 2014269028 A1 AU2014269028 A1 AU 2014269028A1 AU 2014269028 A AU2014269028 A AU 2014269028A AU 2014269028 A AU2014269028 A AU 2014269028A AU 2014269028 A1 AU2014269028 A1 AU 2014269028A1
Authority
AU
Australia
Prior art keywords
angiotensin
peptide
muscular dystrophy
weight
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014269028A
Other languages
English (en)
Inventor
Mark CHAPLEAU
Richard Franklin
Rasna SABHARWAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Constant Therapeutics LLC
Original Assignee
University of Iowa Research Foundation UIRF
Tarix Orphan LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation UIRF, Tarix Orphan LLC filed Critical University of Iowa Research Foundation UIRF
Publication of AU2014269028A1 publication Critical patent/AU2014269028A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2014269028A 2013-04-19 2014-04-18 Angiotensins in muscular dystrophy Abandoned AU2014269028A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361813929P 2013-04-19 2013-04-19
US61/813,929 2013-04-19
US201361818307P 2013-05-01 2013-05-01
US61/818,307 2013-05-01
PCT/US2014/034615 WO2014189634A1 (en) 2013-04-19 2014-04-18 Angiotensins in muscular dystrophy

Publications (1)

Publication Number Publication Date
AU2014269028A1 true AU2014269028A1 (en) 2015-10-22

Family

ID=51933952

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014269028A Abandoned AU2014269028A1 (en) 2013-04-19 2014-04-18 Angiotensins in muscular dystrophy

Country Status (11)

Country Link
US (2) US20160074464A1 (https=)
EP (1) EP2986341A4 (https=)
JP (1) JP2016522178A (https=)
KR (1) KR20160026855A (https=)
CN (1) CN105636645A (https=)
AU (1) AU2014269028A1 (https=)
BR (1) BR112015026286A2 (https=)
CA (1) CA2909002A1 (https=)
MX (1) MX2015014668A (https=)
RU (1) RU2015141336A (https=)
WO (1) WO2014189634A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3169405T3 (da) 2014-07-17 2024-09-23 Univ Southern California Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme
US10973869B2 (en) 2017-05-17 2021-04-13 Constant Therapeutics Llc Methods of treating cardiomyopathy associated with genetic disorders
DK3877376T3 (da) 2018-11-06 2023-10-02 Edgewise Therapeutics Inc Pyridazinonforbindelser og anvendelser deraf
CA3118908A1 (en) * 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
AU2019374812B2 (en) 2018-11-06 2025-03-06 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
CN118680926B (zh) * 2024-07-30 2024-12-20 北京市糖尿病研究所(北京市糖尿病防治办公室) Mas受体激动剂在制备预防或治疗多囊卵巢综合征的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
WO2008089532A1 (en) * 2007-01-26 2008-07-31 Universidade Federal De Minas Gerais - Ufmg Pharmaceutical compositions and methods for treating erectile dysfunction
EP2163259B1 (en) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury
US11707409B2 (en) * 2011-10-25 2023-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
BR132012028005E2 (pt) * 2012-10-31 2014-11-18 Univ Minas Gerais Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares.

Also Published As

Publication number Publication date
EP2986341A1 (en) 2016-02-24
RU2015141336A (ru) 2017-05-22
MX2015014668A (es) 2016-06-30
CN105636645A (zh) 2016-06-01
BR112015026286A2 (pt) 2017-10-10
US20180221433A1 (en) 2018-08-09
EP2986341A4 (en) 2016-11-30
US20160074464A1 (en) 2016-03-17
CA2909002A1 (en) 2014-11-27
JP2016522178A (ja) 2016-07-28
WO2014189634A1 (en) 2014-11-27
KR20160026855A (ko) 2016-03-09

Similar Documents

Publication Publication Date Title
US20180221433A1 (en) Angiotensins in muscular dystrophy
EP2903605B1 (en) Angiotensin in treating brain conditions
US10960045B2 (en) Methods and compositions for the treatment of epidermolysis bullosa
US20180050079A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
US9333233B2 (en) Methods and compositions for the delayed treatment of stroke
US8557958B1 (en) Compositions and methods for treatment of diabetes
US20160296591A1 (en) Compositions and methods for treatment of bdnf-related conditions
US20160199436A1 (en) Methods and compositions for the treatment of amyotrophic lateral sclerosis
AU2014332346B2 (en) Novel peptide compositions
WO2015057403A2 (en) Compositions and methods for treatment of inflammatory bowel disease
US9133241B2 (en) Peptide compositions

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application